Clinical trial
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck…
NCT00412217 · Hoffmann-La Roche, Industry · Terminated
Key facts
| NCT number | NCT00412217 |
|---|---|
| Title | A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer |
| Official title | Phase III Randomized, Controlled Trial of Erlotinib (Tarceva) as Maintenance Therapy in Patients With Squamous Cell Carcinoma of the Head and Neck Treated With Resection and Radiotherapy With or Without Concomitant Chemotherapy With Curative Aim |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug, Other |
| Interventions | Placebo, Erlotinib, Standard of care |
| Enrollment | 94 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Dec 18, 2006 |
| Last update posted | Nov 25, 2016 |
| Countries | Spain |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: